Hormonal
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide induce significant weight loss (up to ~15%) in non-diabetic individuals with obesity, primarily by acting on GLP-1 receptors in the brain (specifically the arcuate nucleus and area postrema) to suppress food intake.
GLP-1 receptor agonists like semaglutide (2.4 mg weekly) are highly effective for weight loss in obese, non-diabetic adults, achieving ~15% body weight reduction. They work by suppressing appetite via brain receptors. Be aware of common side effects like nausea and the likelihood of weight regain if treatment stops, suggesting a need for long-term management.
In non-diabetic individuals with overweight or obesity, with an average BMI of approximately 38, liraglutide administered at a dose of 3.0 mg per day for 56 weeks resulted in an 8% weight loss [10]. In contrast, semaglutide at a dose of 2.4 mg per week for 68 weeks resulted in a 14.9–15.6% weight loss in non-diabetic individuals with overweight or obesity, also with an average BMI of approximately 38 [11, 12]... These findings suggest that GLP-1RAs directly act on GLP-1Rs in the brain to suppress food intake.
Why this rating
The claim is supported by multiple Phase III clinical trials (STEP 1, STEP 8) with large sample sizes and clear statistical significance.
Source
Comparing the anorexigenic effects and mechanisms of gut-derived GLP-1 and its receptor agonists: insights into incretin-based therapies for obesity
Yuta Masuda et al. · Diabetology International · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →